Cellectar Biosciences announces that a patient treated with the company’s lead PDC compound, CLR 131 in the fourth cohort of its Phase I dose escalation safety trial in relapsed or refractory multiple myeloma achieved a partial response.

Cellectar Biosciences (NASDAQ:CLRB) announces that a patient treated with the company’s lead PDC compound, CLR 131 in the fourth cohort of its Phase I dose escalation safety trial in relapsed or refractory multiple myeloma achieved a partial response.
As quoted in the press release:

The primary objective of the study is to determine the highest dose patients can tolerate. The trial’s Data Monitoring Committee (DMC) determined that the fourth cohort dose of 31.25 mCi/m2 was safe and tolerated. Additionally, the company is monitoring signals of efficacy, including surrogate markers M protein and free light chain (FLC). The International Myeloma Working Group (IMWG) defines a PR as a greater than or equal to 50 percent decrease in FLC levels (for patients in whom M protein is unmeasurable) or 50 percent decrease in M protein.
Cohort 4 had three evaluable patients enrolled, each with heavily pretreated relapsed or refractory multiple myeloma (greater than five prior lines) and high degree of tumor burden upon entry into the trial.

Click here to read the full press release.

Source: globenewswire.com

cellectar biosciences clr 131 patient patients Pharmaceutical Investing